Resource Library
Showing 131 to 140 of 330 results
Image
In partnership with Cell Therapy Transplant Canada (CTTC), The Leukemia & Lymphoma Society of Canada (LLSC) is pleased to provide this special, 90-minute webcast on the latest innovations in blood cancer treatment in Canada.
Image
Myelodysplastic syndromes are a group of cancers of the blood and bone marrow. With an MDS, your bone marrow – the soft, spongy material inside your bones – does not produce enough healthy blood cells.
Image
This fact sheet provides an overview of GvHD for healthcare professionals. It reviews presenting symptoms, treatment options and side effects to effectively support your patients.
Image
AML is one of four main types of leukemia. It progresses quickly if untreated. It features cancerous blood cells, often called “blasts.” AML typically affects adults over the age of 65 and is slightly more common in men.
Image
AITL is a rare, fast-growing (aggressive) T-cell subtype of non-Hodgkin lymphoma (NHL) and a common subtype of peripheral T-cell lymphoma (PTCL). AITL typically affects adults over 50.
Image
Learn practical ways to be a proactive agent of change in your own cancer experience or that of your loved one. This webcast was led by Geoffrey Molle and Natasha Sani, from the Community Services Team at LLSC, and will include people impacted by blood cancer. They will offer tips and resources to participate in your own care decisions. Called “self…
Image
CML is a rare type of leukemia (about 15% of all new cases of leukemia are CML) that occurs when a person has a Philadelphia chromosome or another mutation which expresses a new gene (BCR-ABL) inside certain blood cells, causing the bone marrow cells to make too many white blood cells. The Philadelphia chromosome is present in 95% of people with CML, but it…
Image
A blood cancer diagnosis can be overwhelming for children. This illustrated resource is designed to help parents understand the emotions their child may be going through and is offering strategies to manage them.
Image
GvHD is a serious health complication that can result from an allogeneic stem cell transplant. It can happen when donor cells (graft) mistakenly attack the transplant recipient’s (host) tissue and cells.
Image
There are various treatments, depending on whether you have acute or chronic GvHD. Acute GvHD which usually develops within 100 days of an allogeneic stem cell transplant, and chronic GvHD (cGvHD), which develops more than 100 days after the transplant.